Clinical Outcomes after Treatment of Periodontal Intrabony Defects with Nanocrystalline Hydroxyapatite (Ostim) or Enamel Matrix Derivatives (Emdogain): A Randomized Controlled Clinical Trial

Table 2

Clinical outcomes at 6 and 12 months.

Variable	Baseline (BS)	6 months	12 months	Difference (after 6 m)	P value* (Bs–6 m)	Difference (after 12 m)	P value* (Bs–12 m)	P value* (6 m–12 m)
Bone level (mm, mean ± SD)
NHA group	11.8±1.9	10.1±2.1	10.1±2.0	1.7±1.8	0.001	1.6±1.2	<0.001	0.886
EMD group	11.9±2.0	10.2±1.8	10.2±1.8	1.8±1.3	<0.001	1.6±1.3	<0.001	0.919
P value^†	0.867	0.836	0.867	0.958		1.000
RAL (mm, mean ± SD)
NHA group	9.6±2.0	8.0±2.3	8.1±2.4	1.5±2.0	0.004	1.4±1.8	0.003	0.802
EMD group	9.8±1.8	7.8±1.7	7.7±1.6	2.0±1.6	<0.001	2.1±1.6	<0.001	0.635
P value^†	0.640	0.783	0.528	0.427		0.211
PPD (mm, mean ± SD)
NHA group	6.6±1.8	3.9±1.2	4.1±1.7	2.7±1.8	<0.001	2.6±1.8	<0.001	0.706
EMD group	6.6±1.3	3.4±1.2	3.4±1.1	3.2±1.6	<0.001	3.2±1.8	<0.001	0.936
P value^†	0.879	0.191	0.154	0.425		0.312
RGR (mm, mean ± SD)
NHA group	2.9±1.3	4.1±1.3	4.1±1.7	1.2±1.2	0.001	1.1±1.1	0.001	0.891
EMD group	3.3±1.1	4.4±1.2	4.3±1.3	1.2±1.1	<0.001	1.2±1.2	0.001	0.552
P value^†	0.352	0.518	0.596	0.946		0.785

EMD: enamel matrix derivative; NHA: nanocrystalline hydroxyapatite; PPD: probing pocket depths; RAL: relative attachment level; RGR: relative gingival recession; *paired t-test; ^†unpaired t-test. Mean differences are calculated as baseline 6–months, baseline–12 months, and 6–12 months.